Insulin receptor substrates 1 and 2 (IRS1/2) mediate oncogenic signaling from IGF-1R and are upregulated in melanoma cell lines resistant to BRAF inhibitors or derived from patients that developed resistance to vemurafenib treatment. The gene discussed is IRS1; the disease is melanoma.